亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Definition of oxaliplatin sensitivity in patients with advanced colorectal cancer previously treated with oxaliplatin-based therapy

作者
Aimery de Gramont,Benoist Chibaudel,O. Bourges,Nathalie Perez‐Staub,Christophe Tournigand,Frédérique Maindrault‐Gœbel,Thierry André,Annette Kragh Larsen,Pauline Afchain,Christophe Louvet
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:27 (15_suppl): 4024-4024 被引量:14
标识
DOI:10.1200/jco.2009.27.15_suppl.4024
摘要

4024 Background: Oxaliplatin combined with fluoropyrimidines is standard adjuvant therapy in stage III colon cancer and first-line therapy in stage IV colorectal cancer. Oxaliplatin can be reintroduced either at relapse, or after maintenance or after chemotherapy holidays. In this study we defined the sensitivity to oxaliplatin reintroduction based on the oxaliplatin-free interval. Methods: Stage IV pts entered in the OPTIMOX1 and 2 studies (FOLFOX4, FOLFOX7 followed by maintenance without oxaliplatin or chemotherapy holidays) and pts having relapsed after metastases surgery and neoadjuvant or adjuvant FOLFOX for resectable stage IV were eligible if they were rechallenged with FOLFOX. Endpoints were: survival from reintroduction according to interval between the last cycle of oxaliplatin first-line and reintroduction, survival and response at reintroduction according to first FOLFOX response and PFS. Results: 330 pts were included: male 60%, colon/rectum/both 62%/35%/2%, resectable/unresectable: 14%/86%, PS 0–1 / >1: 90%/10%, sites 1/>1: 57%/43%. 23 pts had adjuvant and 22 pts had neoadjuvant chemotherapy. 58 pts (18%) had FOLFOX reintroduction before progression. PFS/OS from reintroduction according to induction FOLFOX response were 8.7/19.5 mths if CR, 4.6/15.2 mths if PR, and 3.2/9.7 mths if SD (P=.0019/.01). PFS/OS from reintroduction according to induction FOLFOX PFS were 2.9/9.3 mths if PFS<6 mths, 4.6/14.7 mths if PFS 6–12 mths and 8.5/23.7 if PFS=12 mths. Table shows results according to intervals. There was no difference between 0–3 and 3–6 mths or 6–9 and 9–12 mths intervals. Conclusions: A prolonged interval between two FOLFOX therapies or a prolonged PFS at first-line FOLFOX predict the efficacy of oxaliplatin reintroduction. The interval between two FOLFOX therapies does not identify a completely refractory population. Resistance (PD rate) is divided by two at each 6 month intervals. [Table: see text] No significant financial relationships to disclose.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
xixi完成签到 ,获得积分10
5秒前
时之王者发布了新的文献求助10
8秒前
花落雨凇的应助被令狐大侠采纳,获得10
16秒前
科研通AI6.3的应助被令狐大侠采纳,获得10
16秒前
科研通AI6.4的应助被令狐大侠采纳,获得10
16秒前
科研通AI65的应助被令狐大侠采纳,获得10
16秒前
深情安青的应助被令狐大侠采纳,获得10
16秒前
酷波er的应助被令狐大侠采纳,获得10
16秒前
16秒前
李爱国的应助被令狐大侠采纳,获得50
16秒前
17秒前
17秒前
u264877完成签到,获得积分10
18秒前
雪白的十八完成签到 ,获得积分10
20秒前
科目三的应助被郭浩瑞采纳,获得10
24秒前
无极微光的应助被科研通管家采纳,获得20
26秒前
ubless607的应助被科研通管家采纳,获得30
26秒前
英姑的应助被科研通管家采纳,获得10
26秒前
Maestro_S的应助被科研通管家采纳,获得10
26秒前
无花果的应助被科研通管家采纳,获得10
26秒前
慕青的应助被科研通管家采纳,获得10
26秒前
秀丽若魔完成签到,获得积分10
27秒前
35秒前
或大或小发布了新的文献求助10
38秒前
华仔的应助被时之王者采纳,获得10
38秒前
39秒前
u236878完成签到,获得积分10
41秒前
42秒前
过时的行云完成签到,获得积分10
43秒前
clm完成签到 ,获得积分10
47秒前
53秒前
痴情的不惜完成签到,获得积分10
55秒前
科研通AI6.2的应助被令狐大侠采纳,获得30
56秒前
彭于晏的应助被令狐大侠采纳,获得10
56秒前
搜集达人的应助被令狐大侠采纳,获得10
56秒前
研友_VZG7GZ的应助被令狐大侠采纳,获得10
56秒前
英俊的铭的应助被令狐大侠采纳,获得10
56秒前
Orange的应助被令狐大侠采纳,获得30
56秒前
慕青的应助被令狐大侠采纳,获得10
57秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185000
求助须知:如何正确求助?哪些是违规求助? 9573966
关于积分的说明 21833855
捐赠科研通 7782482
什么是DOI,文献DOI怎么找? 3434468
关于科研通互助平台的介绍 2558673
邀请新用户注册赠送积分活动 2481178